On March 31, 2023,
Mizuho
initiated coverage of Immunocore Holdings with
a Buy recommendation.
Analyst Price Forecast Suggests 67.32% Upside
As of March 30, 2023,
the average one-year price target for Immunocore Holdings is $82.72.
The forecasts range from a low of $72.72 to a high of $96.60.
The average price target represents an increase of 67.32% from its latest reported closing price of $49.44.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immunocore Holdings
is $178MM, an increase of 23.61%.
The projected annual non-GAAP EPS
is -$0.57.
What are Large Shareholders Doing?
Rtw Investments
holds 5,559K shares
representing 11.55% ownership of the company.
In it’s prior filing, the firm reported owning 4,451K shares, representing
an increase
of 19.93%.
The firm
increased
its portfolio allocation in IMCR by 34.45% over the last quarter.
Rock Springs Capital Management
holds 3,321K shares
representing 6.90% ownership of the company.
In it’s prior filing, the firm reported owning 3,494K shares, representing
a decrease
of 5.20%.
The firm
increased
its portfolio allocation in IMCR by 7.66% over the last quarter.
Baker Bros. Advisors
holds 2,521K shares
representing 5.24% ownership of the company.
No change in the last quarter.
Wellington Management Group Llp
holds 2,153K shares
representing 4.47% ownership of the company.
In it’s prior filing, the firm reported owning 675K shares, representing
an increase
of 68.66%.
The firm
decreased
its portfolio allocation in IMCR by 99.95% over the last quarter.
Price T Rowe Associates
holds 1,334K shares
representing 2.77% ownership of the company.
In it’s prior filing, the firm reported owning 1,164K shares, representing
an increase
of 12.77%.
The firm
increased
its portfolio allocation in IMCR by 36.86% over the last quarter.
What is the Fund Sentiment?
There are 193 funds or institutions reporting positions in Immunocore Holdings.
This is an increase
of
39
owner(s) or 25.32% in the last quarter.
Average portfolio weight of all funds dedicated to IMCR is 0.51%,
a decrease
of 14.34%.
Total shares owned by institutions increased
in the last three months by 15.43% to 31,902K shares.
The put/call ratio of IMCR is 0.20, indicating a
bullish
outlook.
Immunocore Holdings Background Information
(This description is provided by the company.)
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
